These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15273566)

  • 1. Prognostic factors following curative resection for pancreatic adenocarcinoma.
    Jeekel H
    Ann Surg; 2004 Aug; 240(2):384. PubMed ID: 15273566
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant therapy following resection for pancreatic adenocarcinoma.
    Brennan MF
    Surg Oncol Clin N Am; 2004 Oct; 13(4):555-66, vii. PubMed ID: 15350934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Different Treatment Modalities on the Outcome of Pancreatic Cancer.
    Khan M; Ashraf MI; Syed AA; Hanif F
    J Coll Physicians Surg Pak; 2017 Aug; 27(8):470-474. PubMed ID: 28903837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
    Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
    Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined-modality treatment for operable pancreatic adenocarcinoma.
    Pisters PW; Wolff RA; Crane CH; Evans DB
    Oncology (Williston Park); 2005 Mar; 19(3):393-404, 409; discussion 409-10, 412-6. PubMed ID: 15828554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long term survival after pancreatic resection for pancreatic adenocarcinoma].
    Wirtz M; Friess H
    Z Gastroenterol; 2002 Sep; 40(9):849-52. PubMed ID: 12215954
    [No Abstract]   [Full Text] [Related]  

  • 7. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003.
    Meszoely IM; Wang H; Hoffman JP
    Surg Oncol Clin N Am; 2004 Oct; 13(4):685-96, x. PubMed ID: 15350942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
    Heinrich S
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):305-306. PubMed ID: 31262654
    [No Abstract]   [Full Text] [Related]  

  • 11. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study.
    Lygidakis NJ; Sgourakis G; Georgia D; Vlachos L; Raptis S
    Ann Surg; 2002 Dec; 236(6):806-13. PubMed ID: 12454519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation?
    Mukhija D; Sohal DPS; Khorana AA
    Pancreas; 2018 Sep; 47(8):e50-e52. PubMed ID: 30113430
    [No Abstract]   [Full Text] [Related]  

  • 13. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.
    Bergquist JR; Ivanics T; Shubert CR; Habermann EB; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB; Truty MJ
    Ann Surg Oncol; 2017 Jun; 24(6):1731-1738. PubMed ID: 28070725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of prognostic factors associated with early mortality after surgical resection for pancreatic cancer--under-analysis of cumulative survival curve.
    Takamori H; Hiraoka T; Kanemitsu K; Tsuji T; Hamada C; Baba H
    World J Surg; 2006 Feb; 30(2):213-8. PubMed ID: 16425074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
    Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
    Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma.
    Stojadinovic A; Brooks A; Hoos A; Jaques DP; Conlon KC; Brennan MF
    J Am Coll Surg; 2003 Jun; 196(6):954-64. PubMed ID: 12788434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for pancreatic cancer: an evolving paradigm.
    Zhu AX; Clark JW; Willett CG
    Surg Oncol Clin N Am; 2004 Oct; 13(4):605-20, viii. PubMed ID: 15350937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended pancreatectomy and liver perfusion chemotherapy for resectable adenocarcinoma of the pancreas.
    Ishikawa O; Ohhigashi H; Sasaki Y; Furukawa H; Imaoka S
    Digestion; 1999; 60 Suppl 1():135-8. PubMed ID: 10026448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for routine use of adjuvant therapy in pancreatic cancer.
    Kennedy EP; Yeo CJ
    J Surg Oncol; 2007 Jun; 95(7):597-603. PubMed ID: 17230543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer.
    Abe T; Ohuchida K; Endo S; Ookubo F; Mori Y; Nakata K; Miyasaka Y; Manabe T; Ohtsuka T; Nagai E; Oda Y; Nakamura M
    Surgery; 2017 Apr; 161(4):951-958. PubMed ID: 27939334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.